Dr Reddy's Laboratories (FRA:RDDA) 3-Year Revenue Growth Rate : 12.00% (As of Dec. 2023)

View and export this data going back to . Start your Free Trial

What is Dr Reddy's Laboratories 3-Year Revenue Growth Rate?

Dr Reddy's Laboratories's Revenue per Share for the three months ended in Dec. 2023 was €4.77.

During the past 12 months, Dr Reddy's Laboratories's average Revenue per Share Growth Rate was 14.20% per year. During the past 3 years, the average Revenue per Share Growth Rate was 12.00% per year. During the past 5 years, the average Revenue per Share Growth Rate was 11.50% per year. During the past 10 years, the average Revenue per Share Growth Rate was 6.70% per year. Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the average Revenue per Share growth rate.

During the past 13 years, the highest 3-Year average Revenue per Share Growth Rate of Dr Reddy's Laboratories was 46.10% per year. The lowest was -0.50% per year. And the median was 11.50% per year.

Competitive Comparison of Dr Reddy's Laboratories's 3-Year Revenue Growth Rate

For the Drug Manufacturers - Specialty & Generic subindustry, Dr Reddy's Laboratories's 3-Year Revenue Growth Rate, along with its competitors' market caps and 3-Year Revenue Growth Rate data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Dr Reddy's Laboratories's 3-Year Revenue Growth Rate Distribution in the Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Dr Reddy's Laboratories's 3-Year Revenue Growth Rate distribution charts can be found below:

* The bar in red indicates where Dr Reddy's Laboratories's 3-Year Revenue Growth Rate falls into.

Dr Reddy's Laboratories 3-Year Revenue Growth Rate Calculation

This is the 3-year average growth rate of Revenue per Share. The growth rate is calculated using exponential compounding based on the latest four year annual data.

Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the average Revenue per Share growth rate.

Dr Reddy's Laboratories (FRA:RDDA) 3-Year Revenue Growth Rate Explanation

Revenue per Share is the amount of Revenue per outstanding share of the company's stock.

Revenue is income that a company receives from its normal business activities, usually from the sale of goods and services to customers. Revenue is often referred to as the "top line" due to its position on the income statement at the very top. Revenue per share growth rate is used in calculating Predictability Rank, companies with more consistent revenue and earnings growth are ranked high with predictability.

Dr Reddy's Laboratories 3-Year Revenue Growth Rate Related Terms

Thank you for viewing the detailed overview of Dr Reddy's Laboratories's 3-Year Revenue Growth Rate provided by GuruFocus.com. Please click on the following links to see related term pages.

Dr Reddy's Laboratories (FRA:RDDA) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Dr Reddy's Laboratories Ltd (FRA:RDDA) » Definitions » 3-Year Revenue Growth Rate

Traded in Other Exchanges

RDY:USA DRREDDY:India 500124:India RDDA:Germany R1DY34:Brazil

Address

8-2-337, Road No. 3, Banjara Hills, Hyderabad, TG, IND, 500 034

Website

https://www.drreddys.com

Dr. Reddy's is one of the largest generic drug manufacturers in the world. It has a significant presence in North America, a region that makes up roughly half of its generics sales, and it services India (22% of its generics sales), Russia (12%), and certain European and Latin American countries. Beyond simple generics, Dr. Reddy's also has a solid portfolio of injectables which make up 25% of its North America sales. In branded generic markets like India, Dr. Reddy's has established a compelling presence with its strong brand name and earned a top five spot in key therapeutic areas including oncology and gastroenterology. Dr. Reddy's also has an active pharmaceutical ingredient business that manufactures over 150 APIs and sells in over 75 countries.

Dr Reddy's Laboratories (FRA:RDDA) Headlines

No Headlines